Publications by authors named "Matthew D Surman"

Claim this Profile
O
Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors.
Michael E Stokes, Matthew D Surman, Veronica Calvo, David Surguladze, An-Hu Li

Pharmaceutics· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors.
Veronica Calvo, David Surguladze, An-Hu Li, Matthew D Surman, Srikanth Malibhatla

Bioorg Med Chem Lett· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Mark E Gurney, Richard A Nugent, Xuesheng Mo, Janice A Sindac, Timothy J Hagen, Matthew D Surman

J Med Chem· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From preclinical to clinical development: the example of a novel treatment for obesity.
Nicholas A Moore, Bruce J Sargent, Peter R Guzzo, Matthew D Surman

Neurobiol Dis· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridin-2(1H)ones as MCH-1 antagonists for the treatment of obesity.
Mark Hadden, Dustin M Deering, Alan J Henderson, Matthew D Surman, Michele Luche

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tetrahydrocarboline analogs as MCH-1 antagonists.
Alan J Henderson, Dustin Deering, James F Grabowski, Mark Hadden, Xiaowu Jiang, Matthew D Surman

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
Matthew D Surman, Emily E Freeman, James F Grabowski, Mark Hadden, Alan J Henderson

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of vinca alkaloid analogues.
Matthew E Voss, Jeffery M Ralph, Dejian Xie, David D Manning, Xinchao Chen, Matthew D Surman

Bioorg Med Chem Lett· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereo- and regioselectivity of Pd(0)/InI-mediated allylic additions to aldehydes and ketones. In situ generation of allylindium(III) intermediates from N-acylnitroso Diels-Alder cycloadducts and 1-amino-4-acetoxycyclopentenes.
Wenlin Lee, Kyung-Hee Kim, Matthew D Surman, Marvin J Miller

J Org Chem· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regio- and stereoselective ring openings of 3-Aza-2-oxabicyclo[2.2.1]hept-5-ene systems with copper catalyst-modified grignard reagents: application to the synthesis of an inhibitor of 5-lipoxygenase.
Matthew D Surman, Mark J Mulvihill, Marvin J Miller

J Org Chem· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 1,4-benzodiazepines from acylnitroso-derived hetero-Diels-Alder cycloadducts.
Matthew D Surman, Mark J Mulvihill, Marvin J Miller

Org Lett· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis